- Today's Hot Chat Topics
- Member Benefits
- Manage your personalised Watchlist.
- Set up an online Virtual Portfolio.
- Participate in Share Chat.
- See more trades and director dealings.
- Play the Fantasy Share Trading Game.
Share:
HomeShare PricesShare ChatFinance NewsSharecast NewsRegulatory NewsBlogsLive PricesShares BookshopFinance ToolsMembers
Latest Share Chat
Finance & Stock Market News
UPDATE 1-FDA OKs AstraZeneca's influenza vaccine
Wed, 29th Feb 2012 23:46
Feb 29 (Reuters) - U.S. health regulators approved AstraZeneca's vaccine to prevent seasonal i
The U.S. Food and Drug Administration said the vaccine FluMist Quadrivalent, which is manufactured by AstraZeneca's MedImmune unit, is the first vaccine that contain four strains of the influenza virus -- two strains each of influenza A and B.
'A vaccine containing the four virus strains most likely to spread and cause illness during the influenza season offers an additional option to aid in influenza prevention efforts,' said Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research.
(Reporting by Anand Basu in Bangalore; Editing by Maju Samuel) Keywords: ASTRAZENECA/
(anand.basu@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: anand.basu.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
nfluenza in people aged 2-49 years.
The U.S. Food and Drug Administration said the vaccine FluMist Quadrivalent, which is manufactured by AstraZeneca's MedImmune unit, is the first vaccine that contain four strains of the influenza virus -- two strains each of influenza A and B.
'A vaccine containing the four virus strains most likely to spread and cause illness during the influenza season offers an additional option to aid in influenza prevention efforts,' said Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research.
(Reporting by Anand Basu in Bangalore; Editing by Maju Samuel) Keywords: ASTRAZENECA/
(anand.basu@thomsonreuters.com; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging: anand.basu.reuters.com@reuters.net)
COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
